267 related articles for article (PubMed ID: 17786329)
1. Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer.
Coelho V; Dernedde J; Petrausch U; Panjideh H; Fuchs H; Menzel C; Dübel S; Keilholz U; Thiel E; Deckert PM
Int J Oncol; 2007 Oct; 31(4):951-7. PubMed ID: 17786329
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution and efficacy of [131I]A33scFv::CDy, a recombinant antibody-enzyme protein for colon cancer.
Panjideh H; Da Silva Coelho VC; Dernedde J; Bachran C; Förster GJ; Franke J; Fasold P; Fuchs H; Thiel E; Deckert PM
Int J Oncol; 2008 Apr; 32(4):925-30. PubMed ID: 18360720
[TBL] [Abstract][Full Text] [Related]
3. A33scFv-green fluorescent protein, a recombinant single-chain fusion protein for tumor targeting.
Petrausch U; Dernedde J; Coelho V; Panjideh H; Frey D; Fuchs H; Thiel E; Deckert PM
Protein Eng Des Sel; 2007 Dec; 20(12):583-90. PubMed ID: 18033820
[TBL] [Abstract][Full Text] [Related]
4. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase.
Chung-Faye GA; Chen MJ; Green NK; Burton A; Anderson D; Mautner V; Searle PF; Kerr DJ
Gene Ther; 2001 Oct; 8(20):1547-54. PubMed ID: 11704815
[TBL] [Abstract][Full Text] [Related]
5. Production of bifunctional single-chain antibody-based fusion proteins in Pichia pastoris supernatants.
Panjideh H; Coelho V; Dernedde J; Fuchs H; Keilholz U; Thiel E; Deckert PM
Bioprocess Biosyst Eng; 2008 Oct; 31(6):559-68. PubMed ID: 18253756
[TBL] [Abstract][Full Text] [Related]
6. 5-Fluorocytosine combined with Fcy-hEGF fusion protein targets EGFR-expressing cancer cells.
Lan KH; Shih YS; Chang CA; Yen SH; Lan KL
Biochem Biophys Res Commun; 2012 Nov; 428(2):292-7. PubMed ID: 23085230
[TBL] [Abstract][Full Text] [Related]
7. A33scFv-cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy.
Deckert PM; Renner C; Cohen LS; Jungbluth A; Ritter G; Bertino JR; Old LJ; Welt S
Br J Cancer; 2003 Mar; 88(6):937-9. PubMed ID: 12644833
[TBL] [Abstract][Full Text] [Related]
8. An optimized fermentation process for high-level production of a single-chain Fv antibody fragment in Pichia pastoris.
Damasceno LM; Pla I; Chang HJ; Cohen L; Ritter G; Old LJ; Batt CA
Protein Expr Purif; 2004 Sep; 37(1):18-26. PubMed ID: 15294276
[TBL] [Abstract][Full Text] [Related]
9. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery.
Asai T; Trinh R; Ng PP; Penichet ML; Wims LA; Morrison SL
Biomol Eng; 2005 Feb; 21(6):145-55. PubMed ID: 15748688
[TBL] [Abstract][Full Text] [Related]
10. Targeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosine.
Li JJ; Chang SF; Liau II; Chan PC; Liu RS; Yen SH; Wang HE; Chang CA
J Biomed Sci; 2016 Jan; 23():15. PubMed ID: 26801910
[TBL] [Abstract][Full Text] [Related]
11. Genetic construction, expression, and characterization of a single chain anti-CEA antibody fused to cytosine deaminase from yeast.
Zamboni S; Mallano A; Flego M; Ascione A; Dupuis ML; Gellini M; Barca S; Cianfriglia M
Int J Oncol; 2008 Jun; 32(6):1245-51. PubMed ID: 18497986
[TBL] [Abstract][Full Text] [Related]
12. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
Biela BH; Khawli LA; Hu P; Epstein AL
Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
[TBL] [Abstract][Full Text] [Related]
13. Specific tumour localisation of a huA33 antibody--carboxypeptidase A conjugate and activation of methotrexate-phenylalanine.
Deckert PM; Bornmann WG; Ritter G; Williams C; Franke J; Keilholz U; Thiel E; Old LJ; Bertino JR; Welt S
Int J Oncol; 2004 May; 24(5):1289-95. PubMed ID: 15067353
[TBL] [Abstract][Full Text] [Related]
14. Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy.
Sharma SK; Pedley RB; Bhatia J; Boxer GM; El-Emir E; Qureshi U; Tolner B; Lowe H; Michael NP; Minton N; Begent RH; Chester KA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):814-25. PubMed ID: 15701872
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein.
Hao XK; Liu JY; Yue QH; Wu GJ; Bai YJ; Yin Y
Prostate; 2006 Jun; 66(8):858-66. PubMed ID: 16491483
[TBL] [Abstract][Full Text] [Related]
16. Cytosine deaminase-producing human mesenchymal stem cells mediate an antitumor effect in a mouse xenograft model.
You MH; Kim WJ; Shim W; Lee SR; Lee G; Choi S; Kim DY; Kim YM; Kim H; Han SU
J Gastroenterol Hepatol; 2009 Aug; 24(8):1393-400. PubMed ID: 19486256
[TBL] [Abstract][Full Text] [Related]
17. Generation and characterization of a human single-chain fragment variable (scFv) antibody against cytosine deaminase from yeast.
Mallano A; Zamboni S; Carpinelli G; Santoro F; Flego M; Ascione A; Gellini M; Tombesi M; Podo F; Cianfriglia M
BMC Biotechnol; 2008 Sep; 8():68. PubMed ID: 18783590
[TBL] [Abstract][Full Text] [Related]
18. Antitumor therapy mediated by 5-fluorocytosine and a recombinant fusion protein containing TSG-6 hyaluronan binding domain and yeast cytosine deaminase.
Park JI; Cao L; Platt VM; Huang Z; Stull RA; Dy EE; Sperinde JJ; Yokoyama JS; Szoka FC
Mol Pharm; 2009; 6(3):801-12. PubMed ID: 19265397
[TBL] [Abstract][Full Text] [Related]
19. Targeted tumor therapy with a fusion protein of an antiangiogenic human recombinant scFv and yeast cytosine deaminase.
Schellmann N; Panjideh H; Fasold P; Bachran D; Bachran C; Deckert PM; Fuchs H
J Immunother; 2012 Sep; 35(7):570-8. PubMed ID: 22892453
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
